

Central Lancashire Online Knowledge (CLoK)

Title	COVID-19 and the epistemology of epidemiological models at the dawn of AI
Type	Article
URL	https://clock.uclan.ac.uk/id/eprint/35068/
DOI	https://doi.org/10.1080/03014460.2020.1839132
Date	2020
Citation	Ellison, George (2020) COVID-19 and the epistemology of epidemiological models at the dawn of AI. <i>Annals of Human Biology</i> , 47 (6). pp. 506-513. ISSN 0301-4460
Creators	Ellison, George

It is advisable to refer to the publisher's version if you intend to cite from the work.
<https://doi.org/10.1080/03014460.2020.1839132>

For information about Research at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>

Supplementary material

Table S1. A summary of the variation in published reports of key biological, clinical and epidemiological characteristics for SARS-CoV-2 (as of 2nd Aug 2020) and four of the alternative ‘model organisms’ used to offer insight and foresight at the beginning of the COVID-19 pandemic: SARS-CoV-1 (SARS); MERS-CoV (MERS); A/H1N1pdm09 (swine flu); and A/H3N2 (as an example of ‘seasonal influenza’).

Characteristics and parameters:	Disease:	Model organism				
	Pathogen: Status:	COVID-19 SARS-CoV-2 2019-ongoing	SARS-CoV-1 2002-04	MERS-CoV 2012-ongoing	A/H1N1pdm09 2009-10 (swine flu)	A/H3N2 Seasonal influenza
R_0 ¹ (mean, if available; range)		2.6 (mean); 1.4-6.5	2.0-3.0	0.9-1.5	1.2-2.8	0.9-2.2
Incubation period ² (mean; range)		5.1 (2-14) days	4.6 (2-14) days	5.2 (2.0-13.0) days	2.0 (1.0-7.0) days	1.0 (0.5-3.0) days
Serial interval ³ (mean; range, if available)		2.6-8.0 days	8.4 days	7.6 (3.0-19.4) days	2.8 (1.7-7.0) days	3.3 (2.1-3.5) days
Duration – symptom onset to death (median or mean; range, if available)		14 days (median) (range: 6-41 days)	23.7 days (mean) (range: 10-24 days)	12 days (median) (range: 5-23 days)	14.7 days (mean) (range: 8-25 days)	13.4 days (mean) (range: 6-26 days)
Total cases (cumulative/annual)		>17million ⁴	8,098 (to 2004)	2,519 (to Jan 2020)	c800-1,600million	c3.6-65million·yr ⁻¹
Total deaths (cumulative/annual)		>670,000 ⁴	774 (to 2004)	866 (to Jan 2020)	c151,700-575,500	290-650,000·yr ⁻¹
Overall CFR ⁵		2-15%	5-15%	20-36%	0.01-0.12%	0.01-0.33%
CFR ⁵ amongst hospitalised cases		28-62%	c46%	c60%	0.6-3.6%	1.7-25.0%
Last reported case		Ongoing pandemic	2004	Ongoing outbreaks	2010	Seasonal
Asymptomatic		9.3-30.8%	<3-7.5%	13-81%	77-84%	75-85%
Presenting symptoms						
Fever		48-98%	74-100%	84-98%	87-95%	89-96%
Cough		53-82%	29-100%	63-87%	98-99%	85-99%
Sore throat		32%	14-22%	13-25%	64-68%	73-80%
Myalgia		11-63%	25-61%	32-40%	49-85%	50-86%
Breathlessness		24-54%	29-42%	35-72%	35-56%	32-53%
Diarrhoea (Nausea or Vomiting)		0-48% (27%)	11-27% (5-23%)	20-35% (15-21%)	39% (37-64%)	34% (38-69%)
Fatigue		43-81%	31-45%	38%	90-91%	83-94%
Anosmia (Ageusia)		35-68% (40-71%)	c10-15%	c10-15%	c10-15%	c10-15%
Risk factors for severe disease/death						
Age		>60 years	>50 years	>65 years	<18 and >65 years	<5 and ≥65 years
Sex		Male>Female	Male≤Female	Male>Female	Male>Female	Male≥Female
Immunocompromised (IC)		IC	IC	IC	IC	IC
Co-infection (CI)		CI	CI	CI	CI	CI
Comorbidities		Cardio-metabolic; respiratory	Cardio-metabolic; respiratory	Cardio-metabolic; renal; respiratory	Cardio-metabolic; asthma; pregnancy	Cardio-metabolic; renal; pregnancy
Vaccine		Not yet available ⁴	Not yet available	Not yet available	Available	Available
Approved therapeutics		Dexamethasone; Remdesivir ⁴	None approved	None approved	Amandatine; Rimantadine; Oseltamivir; Zanamivir; Baloxavir; Peramivir;	

Table S1. Notes:

1. R_0 – the *average*⁶ number of new infected *cases*⁶ of disease that are directly attributed to the original source case in a population where all individuals are *equally*⁶ susceptible to infection;
2. Incubation period – the time between infection and the first appearance of *symptoms*⁶;
3. Serial interval – the *average*⁶ or *minimum*⁶ time between successive cases in a chain of transmission from one case to the next;
4. Cumulative cases of, and deaths from COVID-19, and the availability of a vaccine or approved therapeutics as of 2nd August 2020;
5. *CFR* (Case Fatality Rate) - the percentage of all individuals *diagnosed with disease*⁶ who die *as a result of the disease*⁶ over a given period of time;
6. *Emphasis* added to reflect the impact that extensive variation in infectivity, susceptibility, and differences in (a)symptomatology, case definition, cause of death classification and sampling frame and context, can have on these parameter estimates.

Table S1. References:

- Al-Tawfiq JA, Gautret P. 2019. Asymptomatic Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: extent and implications for infection control: a systematic review. *Travel Med Infect Dis.* 27:27-32.
- Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, Madani H. 2013. Hospital outbreak of Middle East respiratory syndrome coronavirus. *N Eng J Med.* 369:407-16.
- Belongia EA, Irving SA, Waring SC, Coleman LA, Meece JK, Vandermause M, Lindstrom S, Kempf D, Shay DK. 2010. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. *J Am Med Ass.* 304:1091-8.
- Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. 2014. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. *BMC Inf Dis.* 14:480.
- Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, Bernstein K, Ring L, Landau R, Purisch S, Friedman AM, Fuchs K. 2020. COVID-19 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. *Am J Obstet Gynecol MFM.* 2:100118. DOI: 10.1016/j.ajogmf.2020.100118
- Cabore JW, Karamagi HC, Kipruto H, Asamani JA, Droti B, Seydi AB, Titi-Ofei R, Impouma B, Yao M, Yoti Z, Zawaira F. 2020. The potential effects of widespread community transmission of SARS-CoV-2 infection in the World Health Organization African Region: a predictive model. *BMJ Glob Health.* 5:e002647. DOI: 10.1136/bmjgh-2020-002647
- Calore EE, Uip DE, Perez NM. 2011. Pathology of the swine-origin influenza A (H1N1) flu. *Pathol Res Pract.* 207:86-90.
- Cauchemez S, Fraser C, Van Kerkhove MD, Donnelly CA, Riley S, Rambaut A, Enouf V, van der Werf S, Ferguson NM. 2014. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. *Lancet Infect Dis.* 14:50-6.
- Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. 2015. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. *Eurosurv.* 20:21163. DOI: 10.2807/1560-7917.es2015.20.25.21163
- Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, Feikin DR. 2012. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. *Lancet Infect Dis.* 12:687-95.
- de Pablo GS, Serrano JV, Catalan A, Arango C, Moreno C, Ferre F, Shin JI, Sullivan S, Brondino N, Solmi M, Fusar-Poli P. 2020. Impact of coronavirus syndromes on physical and mental health of health care workers: systematic review and meta-analysis. *J Affect Disord.* 275:48-57.
- De Wit E, Van Doremalen N, Falzarano D, Munster VJ. 2016. SARS and MERS: recent insights into emerging coronaviruses. *Nature Rev Microbiol.* 14:523-34.
- Grant R, Malik MR, Elkholy A, Van Kerkhove MD. A review of asymptomatic and subclinical Middle East respiratory syndrome coronavirus infections. 2019. *Epidemiol Rev.* 41:69-81.
- Hayward AC, Fragaszy EB, Birmingham A, Wang L, Copas A, Edmunds WJ, Ferguson N, Goonetilleke N, Harvey G, Kovar J, Lim MS. 2014. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. *Lancet Resp Med.* 2:445-54.
- Hopkins C, Kumar N. 2020. Anosmia as a potential marker of COVID-19 infection – an update. British Rhinological Society and ENT UK, 1 Apr. <https://www.entuk.org/anosmia-potential-marker-covid-19-infection-%E2%80%93update> Accessed 2 Aug 2020.
- Johns Hopkins University. 2020. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). <https://coronavirus.jhu.edu/map.html> Accessed 2 Aug 2020.
- Jhung MA, Epperson S, Biggerstaff M, Allen D, Balish A, Barnes N, Beaudoin A, Berman L, Bidol S, Blanton L, Blythe D. 2013. Outbreak of variant influenza A (H3N2) virus in the United States. *Clin Infect Dis.* 57:1703-12.
- Lau EH, Hsiung CA, Cowling BJ, Chen CH, Ho LM, Tsang T, Chang CW, Donnelly CA, Leung GM. 2010. A comparative epidemiologic analysis of SARS in Hong Kong, Beijing and Taiwan. *BMC Infect Dis.* 10:1-9.
- Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. 2020. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. *Ann Int Med.* 172:577-82.
- Leung GM, Lim WW, Ho LM, Lam TH, Ghani AC, Donnelly CA, Fraser C, Riley S, Ferguson NM, Anderson RM, Hedley AJ. 2006. Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups. *Epidemiol Infect.* 134:211-21.

- Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. 2020. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *J Trav Med.* Mar 13. DOI: 10.1093/jtm/taaa021
- Mercante G, Ferrelli F, De Virgilio A, Gaiino F, Di Bari M, Colombo G, Russo E, Costantino A, Pirola F, Cugini G, Malvezzi L. 2020. Prevalence of taste and smell dysfunction in coronavirus disease 2019. *J Am Med Ass Otolaryngol Head Neck Surg.* E1-6. DOI:10.1001/jamaoto.2020.1155
- Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. 2020. *Eurosurv.* 25:2000180. DOI: 10.2807/1560-7917.ES.2020.25.10.2000180
- Monto AS, Koopman JS, Lngini IM. 1985. Tecumseh study of illness. XIII. Influenza infection and disease, 1976–1981. *Am J Epidemiol.* 121:811-22.
- Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, Kinoshita R, Yang Y, Yuan B, Akhmetzhanov AR, Linton NM. 2020. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int J Infect Dis.* 94:154-5.
- Paget J, Spreeuwenberg P, Charu V, Taylor RJ, Iuliano AD, Bresee J, Simonsen L, Viboud C. 2019. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. *J Global Health.* 9:1-12.
- Park M, Cook AR, Lim JT, Sun Y, Dickens BL. 2020. A systematic review of COVID-19 epidemiology based on current evidence. *J Clin Med.* 9:967. DOI: 10.3390/jcm9040967
- Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, Storgaard M, Al Khalili S, Simonsen L. 2020. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. *Lancet Infect Dis.* Jul 3. DOI: 10.1016/S1473-3099(20)30484-9
- Placzek HE, Madoff LC. 2014. Association of age and comorbidity on 2009 influenza A pandemic H1N1-related intensive care unit stay in Massachusetts. *Am J Publ Health.* 104:e118-25.
- Rothan HA, Byrareddy SN. 2020. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J Autoimmun.* 109:102433. DOI: 10.1016/j.jaut.2020.102433
- Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. 2020. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. *J Med Virol.* 92:612-7.
- Tekin S, Keske S, Alan S, Batirel A, Karakoc C, Tasdelen-Fisgin N, Simsek-Yavuz S, Isler B, Aydin M, Kapmaz M, Yilmaz-Karadag F. 2019. Predictors of fatality in influenza A virus subtype infections among inpatients in the 2015–2016 season. *Int J Infect Dis.* 81:6-9.
- Van Der Hoek L. 2007. Human coronaviruses: what do they cause? *Antiviral Ther.* 12:651-8.
- Vink MA, Bootsma MC, Wallinga J. 2014. Serial intervals of respiratory infectious diseases: a systematic review and analysis. *Am J Epidemiol* 180:865-75.
- Wang W, Tang J, Wei F. 2020. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. *J Med Virol.* 92:441-7.
- WHO (World Health Organisation) MERS Situation Update – January 2020. 2020. WHO Eastern Mediterranean Regional Office, Cairo. http://www.emro.who.int/images/stories/csr/MERS-CoV_January_2020.png Accessed 2 Aug 2020.
- Wilder-Smith A, Telesman MD, Heng BH, Earnest A, Ling AE, Leo YS. 2005. Asymptomatic SARS coronavirus infection among healthcare workers, Singapore. *Emerg Infect Dis.* 11:1142-45.
- Wong JY, Heath Kelly DK, Wu JT, Leung GM, Cowling BJ. 2013. Case fatality risk of influenza A (H1N1pdm09): a systematic review. *Epidemiol.* 24(6):830-41.
- Xie M, Chen Q. 2020. Insight into 2019 novel coronavirus—an updated interim review and lessons from SARS-CoV and MERS-CoV. *Int J Infect Dis.* 94:119-124.
- Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. 2020. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. *Int Forum Allergy Rhinol.* 10:806–13.
- Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y. 2020. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Resp Med.* 8:475–81.
- Yee J, Unger L, Zdravetz F, Cariello P, Seibert A, Johnson MA, Fuller MJ. 2020. Novel coronavirus 2019 (COVID-19): emergence and implications for emergency care. *J Am Coll Emerg Phys Open.* 1:63-9.
- Yin Y, Wunderink RG. 2018. MERS, SARS and other coronaviruses as causes of pneumonia. *Respirol.* 23:130-7.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 395:1054–62.
- Zumla A, Hui DS, Perlman S. 2015. Middle East respiratory syndrome. *Lancet.* 386:995-1007.




Figure S1. An epistemological framework for the theory-, data- and theory-plus-data-based epidemiological models used to generate insight (through conceptualisation, interpolation and causal inference) and foresight (through simulation, extrapolation and projection), respectively. Each of these models provides (*least wrong* and *most useful*) answers to separate and very different questions; although four are commonly - and somewhat unhelpfully - described (interpolation/classification; extrapolation) or interpreted (simulation; projection) as generating 'predictions'. While models involving simulation, extrapolation and projection might all be capable of generating foresight, their ability to deliver accurate projections (or 'literal predictions') of future events, will depend upon: the (in)stability of the contexts in which they are applied; and how well the models actually reflect the functional mechanisms involved. Importantly, insight from analytical models involving interpolation (→) and causal inference (→) can play a key role in: classifying and characterising such contexts; and strengthening understanding of the underlying 'data generating mechanism' on which accurate and reproducible projections (or 'literal predictions') can then rely.




Figure S2. An illustration of the: (a) theory-based; (b) data-based/driven; and (c) 'theory-plus-data'-based modelling techniques that have been used to generate foresight during the COVID-19 pandemic. The solid and dashed grey curve indicates the true attained and future numbers of cases occurring over time, respectively; the filled black dots indicate the daily number of recorded cases - these being systematically *under*-reported initially, but ultimately *correctly* recorded (from the point indicated by the upward black arrow); and the dark red solid (data-driven) and dashed (theory-driven) curves indicate: (a) simulations based on different theorised parameters; (b) interpolation and extrapolation based on the number of recorded cases; and (c) projections based on theorised parameters that are 'tuned' so that the estimated curve better fits the recorded number of cases (in this instance by changing the theorised R_0 from 2.0 to 2.2).